Back to Browse Journals » Clinical Ophthalmology » Volume 5

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery

Authors Turan-Vural E, Torun-Acar BT, Kivanc SA, Acar S

Published Date June 2011 Volume 2011:5 Pages 881—885


Published 29 June 2011

Ece Turan-Vural¹, Banu Torun-Acar¹, S Argun Kivanc², Suphi Acar¹
¹Haydarpa┼ča Numune Education and Research Hospital, Ophthalmology Clinic, Istanbul, Turkey; ²Umran─▒ye Education and Research Hospital, Ophthalmology Clinic, Istanbul, Turkey

Purpose: To investigate the role of postoperative topical 0.05% cyclosporine A (CsA) eye drops (Restasis®, Allergan Pharmaceutical) in the prevention of recurrence among patients with primary pterygium treated with bare-sclera technique.
Methods: In this prospective randomized controlled study, 36 eyes (34 patients) with primary pterygium were randomized into two groups: Group I comprised 18 eyes (18 patients), and Group II comprised 18 eyes (16 patients). Bare sclera technique was performed in both groups. In Group I, 0.05% CsA was administered postoperatively at 6-hour intervals for 6 months, and Group II did not receive any cyclosporine treatment. The patients were assessed for recurrence, side effects, and complications at postoperative 1 and 7 days as well as each month during the following year. Conjunctival advances which showed a limbus higher than 1 mm were recognized as recurrence.
Results: Recurrence occurred in four patients (22.2%) in Group I and in eight (44.4%) patients in Group II.
Conclusion: Postoperative application of low-dose CsA can be effective for preventing recurrences after primary pterygium surgery.

Keywords: primary pterygium, cyclosporine A, bare sclera

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Usher syndrome associated with Fuchs’ heterochromic uveitis: a case report

Turan-Vural E, Torun-Acar B, Tükenmez N, Sevim S, Buttanri B, Acar S

Clinical Ophthalmology 2011, 5:557-559

Published Date: 29 April 2011

Readers of this article also read:

PERSIST: Physician's Evaluation of Restasis® Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review

Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA

Clinical Ophthalmology 2012, 6:1971-1976

Published Date: 28 November 2012

The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis

Tasci C, Ozkaya S, Ozkara B, Tozkoparan E, Ozkan M, Karadurmus N, Serdar M, Balkan A, Bilgic H

OncoTargets and Therapy 2012, 5:385-390

Published Date: 22 November 2012

Changes in microarchitectural characteristics at the tibial epiphysis induced by collagen-induced rheumatoid arthritis over time

Lee JH, Chun KJ, Kim HS, Kim SH, Lee K-Y, Kim DJ, Lim D

Clinical Interventions in Aging 2012, 7:373-382

Published Date: 18 September 2012

Acceleration of gene transfection efficiency in neuroblastoma cells through polyethyleneimine/poly(methyl methacrylate) core-shell magnetic nanoparticles

Tencomnao T, Klangthong K, Pimpha N, Chaleawlert-umpon S, Saesoo S, Woramongkolchai N, Saengkrit N

International Journal of Nanomedicine 2012, 7:2783-2792

Published Date: 1 June 2012

Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement

Maggie N Tillquist, Thomas M Maddox

Patient Preference and Adherence 2011, 5:91-99

Published Date: 17 February 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009